Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05550532 · ClinicalTrials.gov registry record · Phase 3
A Study of Aticaprant 10 Milligrams (mg) as Adjunctive Therapy in Adult Participants With MDD With Moderate-to-severe Anhedonia and Inadequate Response to Current Antidepressant Therapy
A Phase 3 study of Depressive Disorder, Major and Anhedonia, sponsored by Janssen Research & Development.
- Completed
- Registry status
- Phase 3
- Development phase
- 444
- Enrollment target
- 20
- Study locations
NCT05550532 is a Phase 3 study of Depressive Disorder, Major and Anhedonia that has completed, run by Janssen Research & Development. The registered enrollment target is 444 participants, above the 234-participant average among 52 other Depressive Disorder, Major trials with a reported enrollment target (90% higher). The trial reports 20 study locations across 4 states.
The verdict
NCT05550532, a Phase 3 study of Depressive Disorder, Major and Anhedonia, has completed, sponsored by Janssen Research & Development.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 444 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the efficacy of aticaprant compared with placebo as adjunctive therapy to an antidepressant in improving depressive symptoms in adult participants with major depressive disorder (MDD) with moderate to severe anhedonia (ANH+) who have had an inadequate response to current antidepressant therapy with a selective serotonin reuptake inhibitor (SSRI) or serotonin-norepinephrine reuptake inhibitor (SNRI).
Conditions Studied
Interventions
- OTHER Placebo
- DRUG Aticaprant
Study Locations (20)
Florida
- CNS Clinical Research Group - Coral Springs
- Sarkis Clinical Trials - Gainesville
- New Life Medical Research Center, Inc. - Hialeah
- K2 Medical Research - Maitland
- Vital Care Research - Miami
- Global Medical Institutes - Miami
- LCC Medical Research Institute Inc - Miami
- Florida Research Center Inc. - Miami
- Ezy Medical Research - Miami
- Felicidad Medical Research - Miami
California
- Sunwise Clinical Research - Lafayette
- Pacific Neuropsychiatric Specialists - Orange
- Prospective Research Innovations Inc - Rancho Cucamonga
- University of California San Diego Medical Center - San Diego
- CMB Clinical Trials - Santee
- California Neuroscience Research - Sherman Oaks
- Pacific Clinical Research Medical Group - Upland
- Next Level Clinical Trials, LLC - West Covina
Alabama
- University of Alabama at Birmingham - Birmingham
Colorado
- MCB Clinical Research Centers LLC - Colorado Springs
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 444 participants |
| Start Date | 2022-12-06 |
| Est. Completion | 2024-11-13 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05550532
The ClinicalTrials.gov registry entry for NCT05550532 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 444 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 234-participant average among 52 other Depressive Disorder, Major trials with a reported enrollment target (90% higher). The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Depressive Disorder, Major appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05550532 reports 20 study locations spanning 4 distinct geographic areas - top geographies include Florida, California, Alabama.
Frequently Asked Questions
What is clinical trial NCT05550532 about?
NCT05550532 is a clinical study titled "A Study of Aticaprant 10 Milligrams (mg) as Adjunctive Therapy in Adult Participants With MDD With Moderate-to-severe Anhedonia and Inadequate Response to Current Antidepressant Therapy". The purpose of this study is to evaluate the efficacy of aticaprant compared with placebo as adjunctive therapy to an antidepressant in improving depressive symptoms in adult participants with major depressive disorder (MDD) with moderate to severe anhedonia (ANH+) who have had an inadequate respons...
What is the current status of trial NCT05550532?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 444 participants. The study started on 2022-12-06. Estimated completion is 2024-11-13.
What conditions does trial NCT05550532 study?
This clinical trial studies the following conditions: Depressive Disorder, Major, Anhedonia.
What interventions are being tested in trial NCT05550532?
The interventions under investigation include: Placebo (OTHER), Aticaprant (DRUG).
Who is sponsoring clinical trial NCT05550532?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05550532 being conducted?
This trial has 20 study locations across Alabama, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Depressive Disorder, Major
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Brenipatide in Adult Participants With Major Depressive Disorder
RECRUITING · Phase 3
-
A Study to Evaluate the Efficacy and Safety of Esketamine for Reduction of Symptoms of Major Depressive Disorder
RECRUITING · Phase 3
-
Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms
RECRUITING · Phase 3
-
Psilocybin for Major Depressive Disorder (MDD)
ACTIVE NOT RECRUITING · Phase 3
-
A Study of Aticaprant in Adult and Elderly Participants With Major Depressive Disorder (MDD)
ACTIVE NOT RECRUITING · Phase 3
-
54135419SUI3001: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Adult Participants Assessed to be at Imminent Risk for Suicide
COMPLETED · Phase 3
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.